» Articles » PMID: 35593471

Positive Allosteric Regulation of PAC1-R Up-regulates PAC1-R and Its Specific Ligand PACAP

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

PAC1-R is a recognized preferential receptor for the neuropeptide of pituitary adenylate cyclase-activating polypeptide (PACAP), which mediates neuroprotective and nerve regenerative activities of PACAP. In this study, we found that in both PAC1R-CHO cells with high expression of PAC1R-eGFP and retinal ganglion cells (RGC-5) with the natural expression of PAC1-R, oligo-peptide PACAP(28-38) and the positively charged arginine-rich penetrating peptide TAT, as positive allosteric modulators of PAC1-R, significantly trigger the nuclear translocation of PAC1-R. The chromatin immunoprecipitation (ChIP)-PCR results show that the nuclear translocated PAC1-R binds with the promoter regions of and its specific ligand . The up-regulated promoter activities of and induced by PACAP(28-38) or TAT are positively correlative with the increase of the expression levels of PAC1-R and PACAP. Moreover, the nuclear translocation of PAC1-R induced by PACAP(28-38) or TAT is significantly inhibited by the mutation of PAC1-R on Cys25 and the palmitoylation inhibitor 2-bromopalmitate. Meanwhile, the increase in both PAC1-R and PACAP levels and the neuroprotective activities of PACAP(28-38) and TAT in MPP-induced cell model of Parkinson ' s disease are synchronously inhibited by 2-bromopalmitate, which are positively correlated with the nuclear translocation of PAC1-R induced by PACAP(28-38) or TAT. Bioinformatics analysis and motif enrichment analysis following ChIP-sequencing show that the transcription factors including SP1, Zic2, GATA1, REST and YY1 may be recruited by nuclear PAC1-R and involved in regulating the promoter activities of and . ChIP-sequencing and related bioinformatics analysis show that the downstream target genes regulated by the nuclear PAC1-R are mostly involved in the process of cellular stress and related to neuroprotection, neuronal genesis and development.

Citing Articles

Differential Expression of PACAP/VIP Receptors in the Post-Mortem CNS White Matter of Multiple Sclerosis Donors.

Jansen M, Musumeci G, Castorina A Int J Mol Sci. 2024; 25(16).

PMID: 39201536 PMC: 11354662. DOI: 10.3390/ijms25168850.


Integrated Transcriptomic and Proteomic Study of the Mechanism of Action of the Novel Small-Molecule Positive Allosteric Modulator 1 in Targeting PAC1-R for the Treatment of D-Gal-Induced Aging Mice.

Liang L, Chen S, Su W, Zhang H, Yu R Int J Mol Sci. 2024; 25(7).

PMID: 38612681 PMC: 11011505. DOI: 10.3390/ijms25073872.


Novel Small Molecule Positive Allosteric Modulator SPAM1 Triggers the Nuclear Translocation of PAC1-R to Exert Neuroprotective Effects through Neuron-Restrictive Silencer Factor.

Fan G, Chen S, Liang L, Zhang H, Yu R Int J Mol Sci. 2022; 23(24).

PMID: 36555637 PMC: 9784932. DOI: 10.3390/ijms232415996.


A novel small positive allosteric modulator of neuropeptide receptor PAC1-R exerts neuroprotective effects in MPTP mouse Parkinson's disease model.

Fan G, Chen S, Tao Z, Zhang H, Yu R Acta Biochim Biophys Sin (Shanghai). 2022; 54(9):1349-1364.

PMID: 36082935 PMC: 9909460. DOI: 10.3724/abbs.2022126.

References
1.
Song S, Wang L, Li J, Huang X, Yu R . The allosteric modulation effects of doxycycline, minocycline, and their derivatives on the neuropeptide receptor PAC1-R. Acta Biochim Biophys Sin (Shanghai). 2019; 51(6):627-637. DOI: 10.1093/abbs/gmz045. View

2.
Fornes O, Castro-Mondragon J, Khan A, van der Lee R, Zhang X, Richmond P . JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2019; 48(D1):D87-D92. PMC: 7145627. DOI: 10.1093/nar/gkz1001. View

3.
Gourlet P, Robberecht P, De Neef P, Cauvin A, VANDERMEERS A, Christophe J . Structural requirements for the binding of the pituitary adenylate-cyclase-activating peptide to receptors and adenylate-cyclase activation in pancreatic and neuronal membranes. Eur J Biochem. 1991; 195(2):535-41. DOI: 10.1111/j.1432-1033.1991.tb15734.x. View

4.
Yu R, Li J, Lin Z, Ouyang Z, Huang X, Reglodi D . TAT-tagging of VIP exerts positive allosteric modulation of the PAC1 receptor and enhances VIP neuroprotective effect in the MPTP mouse model of Parkinson's disease. Biochim Biophys Acta Gen Subj. 2020; 1864(8):129626. DOI: 10.1016/j.bbagen.2020.129626. View

5.
Martinez C, Arranz A, Juarranz Y, Abad C, Garcia-Gomez M, Rosignoli F . PAC1 receptor: emerging target for septic shock therapy. Ann N Y Acad Sci. 2006; 1070:405-10. DOI: 10.1196/annals.1317.053. View